Reuters logo
BRIEF-Myovant Sciences secures flexible financing commitments
2017年10月16日 / 下午1点07分 / 1 个月前

BRIEF-Myovant Sciences secures flexible financing commitments

Oct 16 (Reuters) - Myovant Sciences Ltd:

* Myovant Sciences secures flexible financing commitments of up to $140 million

* Myovant Sciences Ltd - ‍notes mature on October 16, 2023​

* Myovant Sciences-‍under terms of agreement with Novaquest, co can request note purchases of up to $60 million at Myovant’s discretion through dec 31, 2018​

* Myovant-Plans to use proceeds to fund ongoing phase 3 development of lead compound relugolix in uterine fibroids, endometriosis & prostate cancer​

* Myovant Sciences Ltd - ‍financing is comprised of a note purchase commitment of up to $60 million and an equity purchase commitment of up to $40 million​

* Says ‍hercules term loan facility provides Myovant an additional debt financing capacity of up to $40 million​

* Myovant Sciences-‍additionally, novaquest has committed to purchase up to additional $20 million of co shares, at Myovant’s discretion through Dec 31, 2018​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below